ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1598

Clinical and Serologic Predictors of Response in Rituximab-Treated Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) – the RIM Study

Rohit Aggarwal1, Ann M. Reed2, Dana P. Ascherman3, Richard J. Barohn4, Brian M. Feldman5, Frederick W. Miller6, Lisa G. Rider6, Michael Harris-Love7, Marc C. Levesque8, Chester V. Oddis9 and the RIM Study Group10, 1Rheumtology, University of Pittsburgh, Pittsburgh, PA, 2Rheumatology, Mayo Clinic, Rochester, MN, 3Medicine/Rheumatology, University of Miami, Miami, FL, 4Department of Neurology, University of Kansas Medical Center, Kansas City, USA, Kansas City, MO, 5Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 6Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 7Geriatrics Service, VA Medical Ctr, Washington, DC, 8Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 9Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 10

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Clinical, laboratory tests and myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Plenary Session II: Discovery 2012

Session Type: Plenary Sessions

Background/Purpose: The Rituximab in Myositis (RIM) Study evaluated 200 refractory myositis patients treated with rituximab, 83% of whom met the definition of improvement (DOI). The aim of this study was to identify the clinical and laboratory predictors of response in this cohort.

Methods: All patients failed corticosteroids and at least 1 other immunosuppressive (IS) agent and received rituximab at weeks 0/1 (Early) or 8/9 (Late). The 1° endpoint in this 44-week trial was time to achieve DOI [³20% improvement in 3 of 6 core set measures (CSM) (includes manual muscle testing (MMT), muscle enzymes, HAQ, patient/parent global, physician global disease activity and extramuscular disease activity) with no >2 CSM worsening by ³25% (excluding MMT)] at 2 consecutive visits. We analyzed the effect of the following baseline variables on the time to DOI: myositis subtype, demographics, laboratory [IgM, IgG, myositis-associated autoantibodies (MAA), CBC, creatinine], damage measures (global, muscle damage and atrophy and organ-related), disease activity and other clinical parameters (skeletal/GI/pulmonary/muscle disease activity, Raynaud, calcinosis, mechanic hands), CSM, medication (early vs. late rituximab, IS agents and corticosteroids) and MAA subset [anti-synthetase (anti-Syn), Mi-2, SRP, TIF1-γ, MJ, other autoantibodies and those without an MAA]. The Wilcoxon test was used to univariately evaluate the association of baseline variables with the time to DOI. A multivariate time-dependent proportional hazard model was built using forward selection (α=0.05) based on univariate variables with p<0.1.

Results: 200 randomized patients (76 PM/76 DM/48 JDM) were analyzed (96 Early/104 Late).Table 1 lists the baseline variables which predicted time to DOI univariately. The multivariate model included autoantibodies (anti-Syn was the best DOI predictor followed by Mi-2 as compared to the ‘no MAA’ subset), and global damage (lower damage had a better response). The effects of global damage diminished by week 20. Myositis subtype (JDM had a better response than adult myositis) was not statistically significant univariately, however, final model was stratified by the subtypes due to their clinical relevance and post hoc had statistical significance in multivariate models.

Conclusion: Anti-Syn and Mi-2 autoAbs strongly predicted improvement in rituximab-treated refractory myositis patients. JDM and lower disease damage predicted more rapid improvement early in course of treatment. It is unclear whether this effect is due to a delayed beneficial effect of rituximab in patients with higher damage and adult PM/DM. These results suggest that early, more aggressive therapy could be considered in some clinical and serologic myositis subsets to achieve a better therapeutic response and to avoid disease-related damage.

Table 1. Univariate predictive factors and final multivariate model.

Univariate variable for predicting future DOI (0.1 level of significance)

Factor

Associated with more rapid achievement of DOI (Hazard Ratio)

p-value for Wilcoxon test for trend

Gender

males (1.28)

p=0.10

Autoantibody

Anti-Syn  (2.83)

Mi-2 (2.48),

Other MAA (1.39)

as compared with no MAA

p=0.001

White blood count

higher counts (1.44)

p=0.04

Muscle damage

lower damage (1.26)

p=0.02

Muscle atrophy

absence of atrophy (1.45)

p=0.02

Global damage

lower damage (1.30)

p=0.004

Most abnormal muscle enzyme

higher result (1.30)

p=0.09

Extramuscular disease activity

higher values (1.26)

p=0.07

Disability index

higher values (1.09)

p=0.09

Multivariate model based on the variables identified in univariate analysis

Autoantibody

Hazard ratio of DOI

P-value (comments)

no MAA

–

(Baseline)

Jo-1/other antiSyn

3.03

<0.01 (for adult PM or DM)

Mi-2

2.49

<0.01(for JDM or adult DM )

Other MAA (SRP, MJ, TIF1-γ, other)

1.38

0.140

Global Damage (dichotomized at median <23 vs. >23) 

0.43

<0.01 for week 8, washes  out by week 20


Disclosure:

R. Aggarwal,
None;

A. M. Reed,
None;

D. P. Ascherman,
None;

R. J. Barohn,
None;

B. M. Feldman,

baxter and Bayer,

2,

Novartis Pharmaceutical Corporation,

9,

Pfizer Inc,

9;

F. W. Miller,
None;

L. G. Rider,
None;

M. Harris-Love,
None;

M. C. Levesque,

Genentech and Biogen IDEC Inc.,

2;

C. V. Oddis,

Genentech and Biogen IDEC Inc.,

9;

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-and-serologic-predictors-of-response-in-rituximab-treated-refractory-adult-and-juvenile-dermatomyositis-dm-and-adult-polymyositis-pm-the-rim-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology